Super-enhancer acquisition drives oncogene expression in triple negative breast cancer

Triple Negative Breast Cancer (TNBC) is a heterogeneous disease lacking known molecular drivers and effective targeted therapies. Cytotoxic chemotherapy remains the mainstay of treatment for TNBCs, which have significantly poorer survival rates compared to other breast cancer subtypes. In addition t...

Descripción completa

Detalles Bibliográficos
Autores principales: Raisner, Ryan, Bainer, Russell, Haverty, Peter M., Benedetti, Kelli L., Gascoigne, Karen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316302/
https://www.ncbi.nlm.nih.gov/pubmed/32584896
http://dx.doi.org/10.1371/journal.pone.0235343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316302/
https://www.ncbi.nlm.nih.gov/pubmed/32584896
http://dx.doi.org/10.1371/journal.pone.0235343

Ejemplares similares